跳至主要内容
临床试验/KCT0000584
KCT0000584已完成未知

A randomized, open-label, multiple-dose, crossover study to investigate the pharmacokinetic drug interaction between rosuvastatin and telmisartan in healthy volunteer

Yuhan0 个研究点目标入组 48 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
Yuhan
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 50(Year)(—)
性别
All

入选标准

  • 1. Healthy male and female aged 20 to 50 with a body mass index(BMI) between 19 and 27 kg/m2
  • 2. Acceptable medical history, physical examination, laboratory tests and EKG, during screening
  • 3. Provision of signed written informed consent

排除标准

  • 1.History of and clinically significant disease
  • 2.Sitting blood pressure meeting the following criteria at screening:
  • 150 = systolic blood pressure =90 (mmHg) and
  • 95 = diastolic blood pressure = 50 (mmHg) amd
  • 100 = Heart rate = 40
  • 3. A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
  • 4. Administration of other investigational products within 90 days prior to the first dosing.
  • 5. Administration of herbal medicine within 30 days or administration of ethical drugs within 14 days or administration of over-the-counter (OTC) drugs within 7 days prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
  • 6.Have AST(SGOT) or/and ALT(SGPT) > 3 times of normal upper limit at the time of screening
  • 7. Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.

研究者

发起方
Yuhan

相似试验

进行中(未招募)
Unknown
A randomized, open-label, multiple-dose, crossover study to compare the safety, pharmacokinetics and pharmacodynamics of DHNP-2001B to RD-02 in healthy adult subjects
KCT0008390DaehanNupharm44
已完成
Unknown
Targeting healthy adult volunteers. The subjects are assigned to sequence 1 or sequence 2 through randomization. Once assigned to the sequence, repeated oral administration of the Test IP(DHNP-2001A) and the Reference IP(RD-01) in that order. The test is divided into Period 1 and 2, and in the case of Period 2 administration, the opposite of Period 1 administration is administered. This clinical trial is designed open-label and aims to compare pharmacokinetic and pharmacokinetic characteristics and safety.
KCT0008519DaehanNupharm44
进行中(未招募)
不适用
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR capsule 32 mg and Dilatrend® tablet 25 mg
KCT0000787Chong Kun Dang48
已完成
不适用
A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteerEndocrine, nutritional and metabolic disease
KCT0001326Dong Hwa Pharm12
已完成
不适用
A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Metformin after oral administration in healthy male volunteerEndocrine, nutritional and metabolic disease
KCT0001386Dong Hwa Pharm12